Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q9NXF7
UPID:
DCA16_HUMAN
Alternative names:
-
Alternative UPACC:
Q9NXF7; B3KPB7
Background:
DDB1- and CUL4-associated factor 16 plays a crucial role as a substrate recognition component for the CUL4-DDB1 E3 ubiquitin-protein ligase complex. This complex is pivotal in mediating the ubiquitination and subsequent proteasome-dependent degradation of nuclear proteins, ensuring cellular homeostasis and protein quality control.
Therapeutic significance:
Understanding the role of DDB1- and CUL4-associated factor 16 could open doors to potential therapeutic strategies. Its involvement in protein degradation pathways highlights its potential as a target for modulating protein levels, offering avenues for the treatment of diseases where protein homeostasis is disrupted.